To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Cowen Healthcare acquires in vitro drug rights for $52.5m
The Paul Royalty Funds spin-out has deployed capital rapidly, making five investments to date from its $500m debut fund, which closed this past July.
